Abstract
We report a rare case of localized prostate cancer with BRCA2 and RB1 co-loss, which is usually found at a more advanced stage with a poor prognosis. A 59-year-old male with prostate cancer was referred to our hospital for surgical treatment. He had schizophrenia that was well controlled by medicine. He had no family history of prostate cancer, breast cancer, or ovarian cancer. His initial PSA was 4.5 ng/mL, and Gleason score 3 + 4 adenocarcinoma was detected in one of 12 needle biopsy cores. Imaging studies demonstrated the clinical stage to be cT2aN0M0. Therefore, robot-assisted laparoscopic radical prostatectomy (RALP) with bilateral nerve sparing was performed. Based on histopathological analysis, the Gleason score was 4 + 3 and the pathological stage was pT2N0M0 with a negative surgical margin. Genetic sequencing identified BRCA2 and RB1 co-loss with limited loss of heterogeneity (LOH). At 12 months after surgery, his PSA level remained < 0.01 ng/mL. This case suggests the importance of early detection of prostate cancer and the possibility of cure for prostate cancer with high malignant potential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jasin M (2016) Haber JE (2016) The democratization of gene editing: insights from site-specific cleavage and double-strand break repair. DNA Repair 44:6–16
Mateo J, Carreira S, Sandhu S et al (2015) DNA repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697–1708
Annala M, Vandekerkhove G, Khalaf D et al (2018) Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 8:444–457
Ku SY, Rosario S, Wang Y et al (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78–83
Abida W, Cyrta J, Heller G et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 116:11428–11436
Mandigo AC, Knudsen KE (2020) Double trouble: concomitant RB1 and BRCA2 depletion evokes aggressive phenotypes. Clin Cancer Res 26:1784–1786
Chakraborty G, Armenia J, Mazzu YZ et al (2020) Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin Cancer Res 26:2047–2064
Kluth M, Scherzai S, Büschek F et al (2018) 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes Cancer 57:504–512
Abida W, Armenia J, Gopalan A et al (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00029
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Research involving human participants
Our study on somatic mutation analysis was approved by the institutional review board of Keio University Hospital (#2018–0015).
Informed consent
Informed consent was obtained from the individual who participated in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Matsumoto, K., Kosaka, T., Nakamura, K. et al. A first Japanese case of BRCA2 and RB1 co-loss organ-confined prostate cancer successfully treated by radical prostatectomy. Int Canc Conf J 10, 170–173 (2021). https://doi.org/10.1007/s13691-021-00469-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-021-00469-z